Acromegaly: all 203 studies

Page 2 of 3. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.

• Buccodental Manifestations in Patients With AcromegalyStatus unknownNCT03401008
• Bone MicroArchitecture in AcromegalyCompletedNCT03225040
• Treatment Patterns and Treatment Outcomes for AcromegalyCompletedNCT03043586
• Strict IGF-1 Control in AcromegalyCompletedNCT02952885Phase 3
• Cardiac (CMRI) Assessment of AcromegalyCompletedNCT02948322Not applicable
• Dynamic Hormone Diagnostics in Endocrine DiseaseCompletedNCT02934399
• PITUItary Carcinoma or Aggressive Tumors REgistry -LyonStatus unknownNCT02854228
• Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic SubjectsCompletedNCT02807233
• Prevalence of Acromegaly in a Diagnostic Consultation for Sleep Apnea SyndromeCompletedNCT02789696Not applicable
• Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mgTerminatedNCT02698384
• Pasireotide LAR and Pegvisomant Study in AcromegalyStatus unknownNCT02668172Phase 4
• Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly CardiomyopathyCompletedNCT02611336Phase 2
• Validation Study of the SAGIT® Instrument in AcromegalyCompletedNCT02539927
• Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin AnaloguesStatus unknownNCT02427295Phase 4
• Assessment of Airway in Patients With Acromegaly for Predicting Successful Tracheal IntubationStatus unknownNCT02403414
• Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.CompletedNCT02396966
• Acromegaly & Sleep ApnoeaCompletedNCT02371057
• Late Effects of Radiosurgery on Acromegaly StudyCompletedNCT02296216Not applicable
• SAGIT for Classification of Patients With Acromegaly in Clinical PracticeCompletedNCT02231593
• Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?CompletedNCT02152124
• Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From AcromegalyStatus unknownNCT02115906
• Phase II Study With ITF2984 in Acromegalic PatientsCompletedNCT02111044Phase 2
• Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.Status unknownNCT02092129
• IGF-I and Free Fatty Acids Isn Glucose Metabolism in AcromegalyCompletedNCT02084095
• Predictive Factors StudyTerminatedNCT02020499
• Description of Sign-and-symptom Associations at Acromegaly Diagnosis.CompletedNCT02012127
• Brain-gut Interaction in Irradiated Patients With AcromegalyStatus unknownNCT02005978
• An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With AcromegalyApproved for marketingNCT01995734
• Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in AcromegalyStatus unknownNCT01902420
• Somatuline Predictive Factors in Acromegaly and NETCompletedNCT01840449
• A Prospective Study of Outcome After Therapy for AcromegalyCompletedNCT01809808
• Epidemiology of Acromegaly in Denmark 1991-2010Status unknownNCT01752621
• Somatostatin Analogue Treatment of Acromegaly: Molecular AspectsCompletedNCT01723748Not applicable
• Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical TargetCompletedNCT01618513Phase 4
• Prospective Study on Changes in AcromegalyStatus unknownNCT01612624
• Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary TumorsCompletedNCT01568359
• Rhinological Outcomes in Endonasal Pituitary SurgeryCompletedNCT01504399
• One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With MacroadenomaCompletedNCT01471405
• Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin AnalogsWithdrawnNCT01371045
• The Observational Study of Growth Hormone-secreting Pituitary TumorsStatus unknownNCT01368133
• Study in Polish Acromegalic Patients Treated With Somatuline AutogelCompletedNCT01333384
• Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly TreatmentCompletedNCT01302652
• Long-term Safety and Efficacy Study of Octreotide Implant in Patients With AcromegalyTerminatedNCT01295060Phase 3
• Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.Status unknownNCT01265121Not applicable
• Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®SuspendedNCT01086982Phase 1
• Peripheral Metabolic Effects of SomatostatinCompletedNCT01062529Not applicable
• Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery AloneCompletedNCT01029275Not applicable
• Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic PatientsCompletedNCT01014793
• Surgical Versus Medical Treatment of AcromegalyCompletedNCT01000090
• Preoperative Lanreotide Treatment in Acromegalic Patients With MacroadenomasStatus unknownNCT00993356Phase 2
• Cardiac Function and Morphology Evaluated by Magnetic Resonance Imaging in Growth Hormone Deficiency and AcromegalyCompletedNCT00970463
• Fractionated Stereotactic Radiotherapy in Patients With AcromegalyCompletedNCT00934271
• Peri-operative Dynamics of the Growth Hormone Axis in Subjects With AcromegalyCompletedNCT00921609
• Lanreotide Levels in AcromegalyStatus unknownNCT00916916
• Open Label Study of Octreotide Implant in Patients With AcromegalyCompletedNCT00913055Phase 2
• Efficacy and Safety Study of Octreotide Implant in Patients With AcromegalyTerminatedNCT00765323Phase 3
• Non Interventional Post Marketing Programme in AcromegalyCompletedNCT00747500
• Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in AcromegalyCompletedNCT00703079
• Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational StudyCompletedNCT00686348
• Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin ResistanceCompletedNCT00663000
• Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic PatientsCompletedNCT00652379Not applicable
• Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After TreatmentCompletedNCT00647179
• Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic PatientsCompletedNCT00642720Phase 4
• Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic PatientsTerminatedNCT00642421Phase 3
• Inter-Assay Growth Hormone and IGF-I VariabilityWithdrawnNCT00638287
• Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic PatientsCompletedNCT00635765Phase 3
• Lanreotide Autogel-120 mg as First-Line Treatment of AcromegalyCompletedNCT00627796Phase 4
• Efficacy and Safety of C2L-OCT-01 PR in Acromegalic PatientsCompletedNCT00616551Phase 3
• Prediction of Tumor Shrinkage in AcromegalyCompletedNCT00616408
• Cardiovascular Outcome After Surgery or Somatostatin AnaloguesCompletedNCT00615004
• Acute Application of Pegvisomant and Octreotide in AcromegalyCompletedNCT00595140Phase 4
• Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist PegvisomantStatus unknownNCT00552851Phase 4
• Physiopathology of Sodium Retention in AcromegalyCompletedNCT00531908Not applicable
• Preoperative Octreotide Treatment of AcromegalyCompletedNCT00521300Phase 4
• Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)WithdrawnNCT00517491Phase 2
• Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following SurgeryCompletedNCT00500227
• Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With AcromegalyCompletedNCT00499993Phase 3
• Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone StatesCompletedNCT00461240
• Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant AcromegalyCompletedNCT00461149Phase 4
• Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid DiseaseCompletedNCT00446082Phase 1
• Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With AcromegalyCompletedNCT00444873Phase 3
• Efficacy of Octreotide Acetate and Cabergoline in Patients With AcromegalyCompletedNCT00376064Phase 4
• Estrogen Treatment in Acromegalic WomenStatus unknownNCT00315107Phase 2
• Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or MacroadenomasTerminatedNCT00242541Phase 4
• Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With AcromegalyCompletedNCT00234572Phase 2/3
• A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or OctreotideCompletedNCT00234520
• Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With AcromegalyCompletedNCT00225979Phase 3
• Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LARCompletedNCT00216398Phase 4
• Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic PatientsCompletedNCT00210457Phase 3
• Octreotide Efficacy and Safety in First-line Acromegalic PatientsCompletedNCT00171886Phase 4
• Canadian Pegvisomant Compassionate Study In Acromegalic PatientsCompletedNCT00151437Phase 4
• Somatuline Autogel: Acromegaly Self/Partner Injection StudyCompletedNCT00149188Phase 4
• Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient SatisfactionCompletedNCT00145405Phase 4
• Long Term Study With B2036-PEGCompletedNCT00143416Phase 3
• Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic PatientsCompletedNCT00128232Phase 3
• Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic PatientsCompletedNCT00088582Phase 2
• A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With AcromegalyCompletedNCT00068042Phase 4
• Pegvisomant And Sandostatin LAR Combination StudyCompletedNCT00068029Phase 4
• A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright SyndromeCompletedNCT00017927Phase 3
• Measurement of Outcome of Surgical Treatment in Patients With AcromegalyStatus unknownNCT00005100

← Acromegaly overview